# OBI-992

Source: https://onco.cc/drugs/obi-992/  
OnCo record `obi-992` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

OBI-992 is an antibody-drug conjugate from OBI Pharma, Inc, in registered phase 2 trials for metastatic cancer.

## Summary

OBI-992 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by OBI Pharma, Inc, in metastatic cancer. An antibody-drug conjugate, as described in the registry record: an antibody against a tumour surface protein carries a cytotoxic payload into the cell. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Code: OBI-992
- Modality: Antibody-drug conjugate
- Mechanism: An antibody-drug conjugate, as described in the registry record: an antibody against a tumour surface protein carries a cytotoxic payload into the cell.

## Sources

- ClinicalTrials.gov: trials of OBI-992: https://clinicaltrials.gov/search?intr=OBI-992

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- trials: [A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors](https://onco.cc/trials/nct06480240/)

---
JSON: https://onco.cc/api/v1/entities/obi-992.json